Effect of chymase inhibitor on vascular proliferation

Japanese Journal of Pharmacology

Volumn 90, Issue 3, 2002, Pages 223-227

  Takai, Shinji ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Chymase; Inhibitor; Vascular proliferation

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; PLACEBO; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; STABILIZING AGENT; SUCCINYLVALYLPROLYLHENYLALANINE SPECIFIC PERMEASE DIPHENYL ESTER; TRANILAST; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN II; CHYMASE;

ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; INTERNAL MAMMARY ARTERY; MAST CELL; NONHUMAN; SAPHENOUS VEIN; STIMULUS RESPONSE; VEIN GRAFT; ANIMAL; ARTERY; BIOSYNTHESIS; CELL DIVISION; ENZYMOLOGY; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHYSIOLOGY; REVIEW; SMOOTH MUSCLE FIBER; TRANSPLANTATION; VASCULAR SMOOTH MUSCLE; VEIN;

ANGIOPLASTY, BALLOON; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ARTERIES; CELL DIVISION; CHYMASES; DOGS; MAST CELLS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VEINS;

EID: 0036859389     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.90.223     Document Type: Conference Paper

References (35)

1. Kim S and Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52, 11-34 (2000)
2. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M and Baumgartner HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245, 186-188 (1989)
3. MERCATOR Study Group: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 86, 100-110 (1992)
4. Faxon DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 2, 362-369 (1995)
5. Roux SP, Clozel JP and Kuhn H: Cilazapril inhibits wall thickening of vein bypass graft in the rat. Hypertension 18, Suppl 4, II70-II76 (1991)
6. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW and Harker LA: Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 18 Suppl 4, II70-II76 (1991)
7. Okunishi H, Miyazaki M, Okamura T and Toda N: Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 149, 1186-1192 (1987)
8. Takai S, Shiota N, Jin D and Miyazaki M: Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol 32, 826-833 (1998)
9. Takai S, Jin D, Sakaguchi M and Miyazaki M: Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 100, 654-658 (1999)
10. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K and Miyazaki M: Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 305, 191-195 (2001)
11. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, and Miyazaki M: Characterization of chymase from human vascular tissues. Clin Chim Acta 265, 13-20 (1997)
12. Takai S, Shiota N, Kobayashi S, Matsumura E and Miyazaki M: Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 412, 86-90 (1997)
13. Caughey GH, Raymond WW and Wolters PJ: Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta 1480, 245-257 (2000)
14. Takai S, Shiota N, Yamamoto D, Okunishi H and Miyazaki M: Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 58, 591-597 (1996)
15. Peters S, Gotting B, Trummel M, Rust H and Brattstrom A: Valsartan for prevention of restenosis after stenting of type B2/C lesions: The VAL-PREST trial. J Invasive Cardiol 13, 93-97 (2001)
16. Green GE, Stertzer SH and Reppert EH: Coronary arterial bypass grafts. Ann Thorac Surg 5, 443 - 450 (1968)
17. Urschel HC, Miller ER, Razzuk MA, Alvares JF, McNamara JJ and Paulson DL: Aorta-to-coronary-artery vein bypass graft for coronary artery occlusive disease. Ann Thorac Surg 8, 114-125 (1969)
18. Fuchs JC, Mitchener JS and Hagen PO: Postoperative changes in autologous vein grafts. Ann Surg 188, 1-15 (1978)
19. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K and Taylor PC: Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 89, 248-258 (1985)
20. Lytle BW, Loop FD, Taylor PC, Simpfendorfer C, Kramer JR, Ratliff BW, Goormastic M and Cosgrove DM: Vein graft disease: The clinical impact of stenoses in saphenous vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg 103, 831-840 (1992)
21. Borland JA, Chester AH, Crabbe S, Parkerson JB, Catravas JD and Yacoub MH: Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac Cardiovasc Surg 116, 206-212 (1998)
22. Nishimoto M, Takai S, Sawada Y, Yuda A, Kondo K, Yamada M, Jin D, Sakaguchi M, Asada K, Sasaki S and Miyazaki M: Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg 121, 729-734 (2001)
23. Takai S, Yuda A, Jin D, Nishimoto M, Sakagichi M, Sasaki S and Miyazaki M: Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett 467, 141-144 (2000)
24. Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, Yamada M, Sawada Y, Kondo K, Asada K, Iwao H, Sasaki S and Miyazaki M: Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 104, 1274-1279 (2001)
25. Yuda A, Takai S, Jin D, Sawada Y, Nishimoto M, Matsuyama N, Asada K, Kondo K, Sasaki S and Miyazaki M: Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins. Life Sci 68, 41-48 (2000)
26. Takai S, Jin D, Nishimoto M, Yuda A, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Sasaki S and Miyazaki M: Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 69, 1725-1732 (2001)
27. Tsunemi K, Takai S, Nishimoto M, Yuda A, Jin D, Sakaguchi M, Sawada Y, Asada K, Kondo K, Sasaki S and Miyazaki M: Lengthy suppression of vascular proliferation by a chymase inhibitor in dog grafted veins. J Thorac Cardiovasc Surg 124, 621-625 (2002)
28. Zhang S, Anderson DF, Bradding P, Coward WR, Baddeley SM, MacLeod JD, McGill JI, Church MK, Holgate ST and Roche WR: Human mast cells express stem cell factor. J Pathol 186, 59-66 (1998)
29. Miyazaki M, Wada T, Shiota N and Takai S: Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 13, Suppl 1, S21-S25 (1999)
30. Miyazaki M, Shiota N, Sakonjo H and Takai S: Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog. Jpn J Pharmacol 79, 455-460 (1999)
31. Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y and Miyazaki M: A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phen yl-7-(2-pyridyloxy)}-2-heptyl] acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther (in press)
32. Shiota N, Okunishi H, Takai S, Mikoshiba I, Sakonjo H, Shibata N and Miyazaki M: Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 99, 1084-1090 (1999)
33. Fukuyama J, Ichikawa K, Miyazawa K, Hamano S, Shibata N and Ujie A: Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol 70, 321-327 (1996)
34. Tamai H, Katoh O, Suzuki S, Fujii K, Aizawa T, Takase S, Kurogane H, Nishikawa H, Sone T, Sakai K and Suzuki T: Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty trial (TREAT). Am Heart J 138, 968-975 (1999)
35. Tamai H, Katoh K, Yamaguchi T, Hayakawa H, Kanmatsuse K, Haze K, Aizawa T, Nakanishi S, Suzuki S, Suzuki T, Takase S, Nishikawa H and Katoh O: The impact of tranilast on restenosis after coronary angioplasty: The Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J 143, 506-513 (2002)